Clinical trial
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent…
NCT00060684 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00060684 |
|---|---|
| Title | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma |
| Official title | A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Low-Grade, Small Lymphocytic, Mixed-Cell, Follicular, Small Cleaved-Cell |
| Intervention type | Drug |
| Interventions | Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab |
| Enrollment | 30 |
| Start date | Dec 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | May 1, 2007 |
| First posted | May 12, 2003 |
| Last update posted | Jan 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: